Sugi Predict

Sugi Predict / Compounds / SCHEMBL516225

SCHEMBL516225

SCHEMBL516225

N[C@@H](CO)C(=O)N[C@H]([C]=O)Cc1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CTSC P53634 5/20 0.48
▸ SLC7A5 Q01650 1/20 0.47
▸ YARS1 P54577 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CTSH P09668 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ MMP2 P08253 1/20 0.43
▸ TAAR1 Q96RJ0 3/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ OPRD1 P41143 2/20 0.39
▸ OPRM1 P35372 1/20 0.39
▸ OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27468879 1.00 CTSC (0.48) CTSCSLC7A5YARS1CYP1A2CYP3A4
SCHEMBL27820556 0.94 CTSC (0.43) CTSCSLC7A5CYP1A2CYP3A4CTSH
SCHEMBL890404 0.91 CTSC (0.57) CTSCSLC7A5YARS1CYP1A2CYP3A4
SCHEMBL890405 0.91 CTSC (0.57) CTSCSLC7A5YARS1CYP1A2CYP3A4
SCHEMBL27650437 0.89 SLC7A5 (0.51) CTSCSLC7A5YARS1MMP2OPRD1
SCHEMBL9143188 0.86 CTSC (0.67) CTSCSLC7A5YARS1CYP1A2CYP3A4
SCHEMBL9293695 0.86 CTSC (0.67) CTSCSLC7A5YARS1CYP1A2CYP3A4
SCHEMBL8893265 0.86 CTSC (0.67) CTSCSLC7A5YARS1CYP1A2CYP3A4
SCHEMBL5996736 0.86 CTSC (0.67) CTSCSLC7A5YARS1CYP1A2CYP3A4
SCHEMBL28163385 0.85 FOLH1 (0.47) CTSCSLC7A5CYP1A2CYP3A4CTSH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896711-B2 Fluorogenic or fluorophoric compounds and uses thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-02-20 — — US disclosed
US-20160340709-A1 FLUOROGENIC OR FLUOROPHORIC COMPOUNDS AND USES THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-11-24 — — US disclosed
US-9493522-B2 Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-15 — — US disclosed
US-9434975-B2 Fluorogenic or fluorophoric compounds and uses thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-09-06 — — US disclosed
CN-103476761-B Fluorescence immunogenic compound or fluorescent compound and application thereof 3M创新有限公司 2016-08-03 — — CN disclosed
US-20150309047-A1 CIRCULATING PROTEOLYTIC BIOMARKERS OF CELL DEATH AND METHODS FOR THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-10-29 — — US disclosed
CN-104642626-A Stomach-quieting tea and preparation method thereof JINGXI SHOUBAI HEALTHY TEA DRINKS CO LTD 2015-05-27 — — CN disclosed
EP-2691383-B1 FLUOROGENIC OR FLUOROPHORIC COMPOUNDS AND USES THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2015-01-21 — — EP disclosed
CN-103319282-B Disease and insect resistant fertilizer produced by traditional Chinese medicines and preparation technology thereof WEI WENLI 2014-08-06 — — CN disclosed
US-20140186878-A1 FLUOROGENIC OR FLUOROPHORIC COMPOUNDS AND USES THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-07-03 — — US disclosed
CN-1229134-C External Chinese patent medicines for curing periarthritis humeroscapularis and myotenositis XU XIAOJIE (CN) 2005-11-30 — — CN disclosed
CN-1202859-C Chinese medicine for treating protrasion of the lumber intervertebral disci XU XIAOJIE (CN) 2005-05-25 — — CN disclosed
CN-1180815-C Tumor treating medicine 于玺长 2004-12-22 — — CN disclosed
CN-1539470-A External Chinese patent medicines for curing periarthritis humeroscapularis and myotenositis 徐小杰 2004-10-27 — — CN disclosed
CN-1528375-A Chinese medicine for treating protrasion of the lumber intervertebral disci 徐小杰 2004-09-15 — — CN disclosed
CN-1132616-C Traditional Chinese medicine for treating arthralgia-syndrome LIU DAINZHANG (CN) 2003-12-31 — — CN disclosed
CN-1383856-A Tumor treating medicine YU XICHANG (CN) 2002-12-11 — — CN disclosed
CN-1358532-A Traditional Chinese medicine for treating arthralgia-syndrome LIU DAINZHANG (CN) 2002-07-17 — — CN disclosed
US-4111923-A LUTEINIZING HORMONE RELEASING FACTOR ANTAGONISTS PARKE, DAVIS & COMPANY (US) 1978-09-05 — — US disclosed
US-4086219-A LUTEINIZING HORMONE RELEASING FACTOR ANTAGONISTS PARKE, DAVIS & COMPANY (US) 1978-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140186878-A1 FLUOROGENIC OR FLUOROPHORIC COMPOUNDS AND USES THEREOF FDPS, FOS, PFKFB1 CTSC 1598/4885SLC7A5 1335/4885YARS1 2820/4885
US-20160340709-A1 FLUOROGENIC OR FLUOROPHORIC COMPOUNDS AND USES THEREOF FDPS, FOS, PFKFB1 CTSC 1598/4885SLC7A5 1335/4885YARS1 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.